Search

Bakhos A Tannous

age ~51

from Lynnfield, MA

Also known as:
  • Tannous Bakhos Bakhos
  • Tannous Bakhos
  • Bakhos S
Phone and address:
4 Thistle Ln, South Lynnfield, MA 01940

Bakhos Tannous Phones & Addresses

  • 4 Thistle Ln, Lynnfield, MA 01940
  • 131 Webster St, Malden, MA 02148 • 781 397-0494
  • 131 Webster St APT 2, Malden, MA 02148
  • 117 Laurel St, Malden, MA 02148 • 781 667-2068
  • 191 Bunker Hill St, Charlestown, MA 02129 • 617 242-2343
  • 4 Thistle Ln, Lynnfield, MA 01940 • 781 667-2068

Work

  • Company:
    Massachusetts general hospital
    2008
  • Position:
    Director, experimental therapeutics and molecular imaging laboratory

Industries

Research

Resumes

Bakhos Tannous Photo 1

Associate Professor At Harvard Medical School

view source
Position:
Director, Experimental Therapeutics and Molecular Imaging Laboratory at Massachusetts General Hospital, Associate Professor at Harvard Medical School, Associate Neuroscientist at Massachusetts General Hospital
Location:
Greater Boston Area
Industry:
Research
Work:
Massachusetts General Hospital since 2008
Director, Experimental Therapeutics and Molecular Imaging Laboratory

Harvard Medical School since Oct 2002
Associate Professor

Massachusetts General Hospital since Oct 2002
Associate Neuroscientist

University of Windsor - Windsor, On, Canada 1992 - 2002
Ph.D.

Us Patents

  • Secreted Luciferase Fluorescent Protein Conjugate Nucleic Acid Construct And Uses Thereof

    view source
  • US Patent:
    20100035287, Feb 11, 2010
  • Filed:
    Oct 12, 2007
  • Appl. No.:
    12/444068
  • Inventors:
    Bakhos A. Tannous - Malden MA, US
    Xandra Breakefield - Newton MA, US
    Jeffrey W. Hewett - Duxbury MA, US
  • Assignee:
    THE GENERAL HOSPITAL CORPORATION - Boston MA
  • International Classification:
    C12Q 1/66
    C07H 21/00
  • US Classification:
    435 8, 536 232
  • Abstract:
    The present invention relates generally to methods to monitor the transport of proteins through the secretory pathway, and methods to monitor ER stress. In particular, the present invention relates to methods to monitor, in real-time, the processing of protein through the secretory pathway, which can be monitored both at a subcellular level by florescence visualization and quantitatively by detecting the secreted luciferase reporter protein. The present invention also relates to methods to assess biological processes in cells, in particular the secretory pathway and ER stress, as well as methods to identify agents which augment or inhibit the secretory pathway and/or ER stress. The present invention also relates to compositions and nucleic constructs encoding a secreted luciferase-fluorescent protein conjugate for methods to monitor protein trafficking in the cell by simultaneous detection of fluorescence and luciferase secretion.
  • Gaussia Luciferase Variant For High-Throughput Screening

    view source
  • US Patent:
    20120122182, May 17, 2012
  • Filed:
    Jun 30, 2010
  • Appl. No.:
    13/381788
  • Inventors:
    Bakhos A. Tannous - Malden MA, US
    Casey Maguire - Arlington MA, US
  • Assignee:
    THE GENERAL HOSPITAL CORPORATION - BOSTON MA
  • International Classification:
    C12N 9/02
    C12N 5/04
    C12N 5/071
    C12N 1/21
    C12N 5/07
    C12N 15/53
    C12N 1/19
  • US Classification:
    435189, 536 232, 435419, 4352542, 4352523, 435348, 435325, 435354, 435363, 435366, 435352, 435350, 435351
  • Abstract:
    Described herein is a variant of wild type Gaussia luciferase that catalyzes glow-type emission kinetics suited for high-throughput functional screening applications. Polypeptides, functional fragments, variants, and nucleic acids that encode the enhanced luciferase are further described. One such polypeptide corresponds to wild type Gaussia luciferase with a substitution mutation of I for M at position 43 of the mature peptide. Methods of use, assay systems and kits that contain the polypeptides and/or nucleic acids are further described.
  • Secreted Luciferase For Ex Vivo Monitoring Of In Vivo Processes

    view source
  • US Patent:
    20090235370, Sep 17, 2009
  • Filed:
    Jan 16, 2009
  • Appl. No.:
    12/355055
  • Inventors:
    Bakhos A. Tannous - Malden MA, US
  • Assignee:
    THE GENERAL HOSPITAL CORPORATION - BOSTON MA
  • International Classification:
    A01K 67/027
    C12Q 1/66
    C12N 5/06
  • US Classification:
    800 3, 435 8, 435325, 800 13, 800 14
  • Abstract:
    The present invention generally relates to a methods, compositions and assays for real-time monitoring of the progression of a disease, such as a cancer in a subject, by measuring the level of bioluminescence signal in a biological sample obtained from a subject, where the bioluminescence signal is from a secreted luciferase protein expressed by a cell or tissue in the subject. One aspect of the present invention relates to administering to a subject a nucleic acid encoding a secreted luciferase, and in some embodiments, a disease or a diseased tissue such as tumor cells expresses the secreted luciferase protein, which is monitored in a biological sample, such as blood or urine obtained from a subject. One aspect of the invention relates to analysis of a secreted luciferase protein by measuring the level in a biological sample obtained from the subject without the need for invasive monitoring procedures.
  • Ribonucleotide Reductase Inhibitors Sensitize Tumor Cells To Dna Damaging Agents

    view source
  • US Patent:
    20160317531, Nov 3, 2016
  • Filed:
    Jun 19, 2014
  • Appl. No.:
    14/900286
  • Inventors:
    - Boston MA, US
    Bakhos A Tannous - Lynnfield MA, US
  • International Classification:
    A61K 31/495
    A61K 31/17
  • Abstract:
    The present invention relates to methods for treatment of tumors comprising administering to a subject in need thereof a DNA damaging agent and a ribonucleotide reductase inhibitor. The ribonucleotide reductase inhibitor can sensitize tumor cells to the DNA damaging agent, thus permitting greater treatment efficacy than the DNA damaging agent alone. The methods described herein are generally useful for treating any tumor that can benefit from this combination therapy. In particular, the methods described herein are useful for treating tumors that are resistant or have the propensity to develop resistance to certain DNA damaging agents. Further provided in the prevent invention are compositions comprising a DNA damaging agent and a ribonucleotide reductase inhibitor.

Classmates

Bakhos Tannous Photo 2

Bakhos Tannous

view source
Schools:
L'Essor High School Windsor Morocco 1987-1991
Community:
Suzanne Beers, Alain Dubuc, Lou Garou, Steve Beaudoin, Matt Adamson, Natalie Krapac, Monique Boutin, Chris Hiuser, Gerald Martineau, Sandra Poirier, Mario Bouchard

Youtube

2022 FIRST LOOK | Bakhos Tannous, PhD

Olfactory Ensheathing Glia: An Unconventional Cell for Cancer Gene/Cel...

  • Duration:
    9m 1s

Noninvasive Techniques in Brain Tumor Treatment

In this video, Bakhos Tannous, PhD, director of the Experimental Thera...

  • Duration:
    2m

Interview MTV with Fr Bakhos Tannous

Fr. Dr. Bakhos Tannous, Superior of the Monastery of Our Lady of Salva...

  • Duration:
    9m 54s

Dr. Tannous Awarded $50,000 for DIPG Research

In October 2017 a member of the DIPG Collaborative surprised Dr. Bakho...

  • Duration:
    1m 1s

New Therapies for Brain Tumors

Brain tumors are difficult to treat because the brain has natural barr...

  • Duration:
    2m 9s

Dr. Oliver Tannous - Orthopedic Spine Surgeon

Meet Dr. Robinson. How he fell in love with orthopedic surgery and why...

  • Duration:
    2m 5s

Kfarabida Nol 2014

Mercredi 24-12-2014 (minuit)

  • Duration:
    1m 50s

40 Day Mass for the late Margo Tannous 6pm | ...

Fr Maroun El Kazzi.

  • Duration:
    1h 31m 17s

Get Report for Bakhos A Tannous from Lynnfield, MA, age ~51
Control profile